488 related articles for article (PubMed ID: 18394720)
21. Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation.
Schlosburg JE; Kinsey SG; Lichtman AH
AAPS J; 2009 Mar; 11(1):39-44. PubMed ID: 19184452
[TBL] [Abstract][Full Text] [Related]
22. Critical enzymes involved in endocannabinoid metabolism.
Basavarajappa BS
Protein Pept Lett; 2007; 14(3):237-46. PubMed ID: 17346227
[TBL] [Abstract][Full Text] [Related]
23. Does the hydrolysis of 2-arachidonoylglycerol regulate its cellular uptake?
Fowler CJ; Ghafouri N
Pharmacol Res; 2008 Jul; 58(1):72-6. PubMed ID: 18675915
[TBL] [Abstract][Full Text] [Related]
24. The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis.
Navarria A; Tamburella A; Iannotti FA; Micale V; Camillieri G; Gozzo L; Verde R; Imperatore R; Leggio GM; Drago F; Di Marzo V
Pharmacol Res; 2014 Sep; 87():151-9. PubMed ID: 24861565
[TBL] [Abstract][Full Text] [Related]
25. Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain.
Valenti M; Viganò D; Casico MG; Rubino T; Steardo L; Parolaro D; Di Marzo V
Cell Mol Life Sci; 2004 Apr; 61(7-8):945-50. PubMed ID: 15095014
[TBL] [Abstract][Full Text] [Related]
26. Anandamide hydrolysis: a new target for anti-anxiety drugs?
Gaetani S; Cuomo V; Piomelli D
Trends Mol Med; 2003 Nov; 9(11):474-8. PubMed ID: 14604824
[TBL] [Abstract][Full Text] [Related]
27. Ex vivo imaging of fatty acid amide hydrolase activity and its inhibition in the mouse brain.
Glaser ST; Gatley SJ; Gifford AN
J Pharmacol Exp Ther; 2006 Mar; 316(3):1088-97. PubMed ID: 16278311
[TBL] [Abstract][Full Text] [Related]
28. Progesterone up-regulates anandamide hydrolase in human lymphocytes: role of cytokines and implications for fertility.
Maccarrone M; Valensise H; Bari M; Lazzarin N; Romanini C; Finazzi-Agrò A
J Immunol; 2001 Jun; 166(12):7183-9. PubMed ID: 11390466
[TBL] [Abstract][Full Text] [Related]
29. Alteration of endocannabinoid system in human gliomas.
Wu X; Han L; Zhang X; Li L; Jiang C; Qiu Y; Huang R; Xie B; Lin Z; Ren J; Fu J
J Neurochem; 2012 Mar; 120(5):842-9. PubMed ID: 22176552
[TBL] [Abstract][Full Text] [Related]
30. Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide.
Fowler CJ; Jonsson KO; Tiger G
Biochem Pharmacol; 2001 Sep; 62(5):517-26. PubMed ID: 11585048
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task.
Varvel SA; Wise LE; Niyuhire F; Cravatt BF; Lichtman AH
Neuropsychopharmacology; 2007 May; 32(5):1032-41. PubMed ID: 17047668
[TBL] [Abstract][Full Text] [Related]
32. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet.
Starowicz KM; Cristino L; Matias I; Capasso R; Racioppi A; Izzo AA; Di Marzo V
Obesity (Silver Spring); 2008 Mar; 16(3):553-65. PubMed ID: 18239598
[TBL] [Abstract][Full Text] [Related]
33. Effect of nitric oxide donors on membrane tritium accumulation of endocannabinoids and related endogenous lipids.
Thors L; Fowler CJ
Eur J Pharmacol; 2009 Oct; 621(1-3):10-8. PubMed ID: 19715690
[TBL] [Abstract][Full Text] [Related]
34. The novel reversible fatty acid amide hydrolase inhibitor ST4070 increases endocannabinoid brain levels and counteracts neuropathic pain in different animal models.
Caprioli A; Coccurello R; Rapino C; Di Serio S; Di Tommaso M; Vertechy M; Vacca V; Battista N; Pavone F; Maccarrone M; Borsini F
J Pharmacol Exp Ther; 2012 Jul; 342(1):188-95. PubMed ID: 22514334
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate.
Vandevoorde S; Fowler CJ
Br J Pharmacol; 2005 Aug; 145(7):885-93. PubMed ID: 15895107
[TBL] [Abstract][Full Text] [Related]
36. Endocannabinoids: synthesis and degradation.
Di Marzo V
Rev Physiol Biochem Pharmacol; 2008; 160():1-24. PubMed ID: 18481028
[TBL] [Abstract][Full Text] [Related]
37. Fatty acid amide hydrolase inhibitors--progress and potential.
Khanna IK; Alexander CW
CNS Neurol Disord Drug Targets; 2011 Aug; 10(5):545-58. PubMed ID: 21631410
[TBL] [Abstract][Full Text] [Related]
38. The fatty acid amide hydrolase (FAAH).
Deutsch DG; Ueda N; Yamamoto S
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):201-10. PubMed ID: 12052036
[TBL] [Abstract][Full Text] [Related]
39. Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as "dual-target" analgesics.
Maione S; Costa B; Piscitelli F; Morera E; De Chiaro M; Comelli F; Boccella S; Guida F; Verde R; Ortar G; Di Marzo V
Pharmacol Res; 2013 Oct; 76():98-105. PubMed ID: 23911581
[TBL] [Abstract][Full Text] [Related]
40. Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase.
Reggio PH; Traore H
Chem Phys Lipids; 2000 Nov; 108(1-2):15-35. PubMed ID: 11106780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
